GlassScriptPhysician profile
Jose B Melo
NPI 1922014547
$35,653.95
in general payments reported to CMS, 2019-2025
77 companies · $5,475 in 2025
The $5,475 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,414 · 2020: $3,903 · 2021: $5,400 · 2022: $5,168 · 2023: $5,605 · 2024: $5,689 · 2025: $5,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $1,768 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,835.21 |
| Education | $1,767.75 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,533.39 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $2,997.03 | 2019-2025 | |
| Pfizer INC. | $2,276.68 | 2019-2025 | |
| Janssen Biotech, INC. | $2,024.16 | 2019-2025 | Erleada, Imbruvica, Darzalex |
| Genentech USA, INC. | $1,896.05 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Merck Sharp & Dohme LLC | $1,740.98 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $1,622.54 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $1,484.54 | 2019-2025 | Tivdak, Tukysa, Adcetris |
| Incyte Corporation | $1,308.40 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $1,198.11 | 2019-2023 | Xospata, Xtandi, Padcev |
| Eisai INC. | $1,105.67 | 2019-2025 | |
| Exelixis INC. | $1,050.38 | 2019-2025 | Cabometyx |
| Celgene Corporation | $985.99 | 2019-2025 | Pomalyst, Reblozyl |
| Genzyme Corporation | $900.07 | 2019-2025 | |
| Lilly USA, LLC | $819.59 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $796.17 | 2019-2025 | Lumakras, Kyprolis, Mvasi |
| Abbvie INC. | $773.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $759.97 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Rigel Pharmaceuticals, INC. | $594.97 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Daiichi Sankyo INC. | $498.53 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Array Biopharma INC | $447.76 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $414.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $341.46 | 2020-2025 | Ojjaara, Blenrep |
| Bayer Healthcare Pharmaceuticals INC. | $337.77 | 2019-2025 | |
| Deciphera Pharmaceuticals INC. | $303.28 | 2021-2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $295.71 | 2022-2025 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $289.00 | 2022-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $277.07 | 2019-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $266.87 | 2020-2025 | Zepzelca |
| Taiho Oncology, INC. | $247.65 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.78 | 2019-2025 | |
| Foundation Medicine, INC. | $242.90 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $209.59 | 2019-2025 | Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $209.56 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $203.53 | 2020-2025 | Xpovio |
| Mirati Therapeutics, INC. | $198.52 | 2023-2024 | Krazati |
| Beigene USA, INC. | $189.64 | 2022-2024 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $166.58 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $144.02 | 2019-2025 | Bavencio |
| Dova Pharmaceuticals | $143.66 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $140.87 | 2022-2024 | Clonoseq |
| Servier Pharmaceuticals LLC | $133.08 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $105.21 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Shield Therapeutics INC | $83.33 | 2024-2025 | |
| Sobi, INC | $82.59 | 2022-2025 | |
| Blueprint Medicines Corporation | $80.40 | 2023-2025 | Ayvakit |
| Alnylam Pharmaceuticals INC. | $76.31 | 2023-2025 | Amvuttra, Givlaari |
| Tolmar, INC. | $70.33 | 2024-2025 | Rubraca, Eligard |
| Beone Medicines USA, INC. | $67.77 | 2025 | Brukinsa |
| Tg Therapeutics, INC. | $67.69 | 2021-2022 | |
| Sirtex Medical INC | $64.62 | 2022-2023 | Sir-Spheres Microspheres |
| Agios Pharmaceuticals, INC. | $62.61 | 2019-2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $61.36 | 2025 | Danziten |
| Kyowa Kirin, INC. | $61.34 | 2022-2024 | Poteligeo |
| Myovant Sciences INC. | $59.05 | 2021 | |
| Pharmaand Gmbh | $58.61 | 2025 | Rubraca |
| Amneal Pharmaceuticals LLC | $54.25 | 2023-2024 | Avastin, Neupogen, Neulasta |
| Stemline Therapeutics INC. | $54.05 | 2025 | Orserdu |
| Gilead Sciences, INC. | $52.34 | 2021-2024 | |
| Geron Corporation | $48.97 | 2025 | Rytelo |
| Caris Mpi, INC. | $48.42 | 2025 | Mi Cancer Seek |
| Teva Pharmaceuticals USA, INC. | $47.39 | 2019 | |
| Springworks Therapeutics, INC. | $46.68 | 2025 | Ogsiveo |
| Acceleron Pharma, INC. | $45.04 | 2020 | |
| Sumitomo Pharma America, INC. | $44.67 | 2024 | Orgovyx |
| Morphosys, US INC. | $41.25 | 2022 | |
| Recordati_rare_diseases_inc. | $40.73 | 2024 | Sylvant |
| Epizyme, INC. | $37.32 | 2020-2021 | |
| Tersera Therapeutics LLC | $29.42 | 2025 | Zoladex |
| Sun Pharmaceutical Industries INC. | $24.88 | 2020 | |
| Sandoz INC. | $24.18 | 2020-2021 | |
| Secura Bio, INC. | $23.68 | 2020 | |
| Adc Therapeutics America, INC. | $21.00 | 2022 | |
| G1 Therapeutics, INC. | $18.33 | 2022 | |
| Advanced Accelerator Applications | $18.26 | 2020 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
Drugs and devices associated with these payments
Keytruda $1,020Lynparza $800Enhertu $673Lenvima $538Venclexta $496Opdivo $443Tukysa $441Erleada $426Sarclisa $425Tivdak $398Cabometyx $376Braftovi $364Xtandi $361Mektovi $339Rezlidhia $332Tavalisse $332Orgovyx $311Ibrance $310Scemblix $291Tagrisso $288Verzenio $286Jakafi $270Krazati $260Talzenna $250Reblozyl $249Imbruvica $246Jaypirca $246Adcetris $242Imfinzi $237Elrexfio $229Fruzaqla $227Padcev $219Brukinsa $213Monoferric $213Bosulif $203Pomalyst $199Lonsurf $194Inqovi $194Polivy $188Welireg $176Lorbrena $174Libtayo $166Qinlock $165Nubeqa $158Fotivda $150Ninlaro $142Gavreto $137Injectafer $131Tecentriq $129Inlyta $128Xofigo $122Tasigna $120Opdualag $116Comirnaty $116Alunbrig $114Retevmo $113Rubraca $110Ultomiris $109Clonoseq $102Pluvicto $96.29Zepzelca $91.22Itovebi $86.52Accrufer $83.33Keytruda Qlex $83.02Ayvakit $80.40Elahere $79.93Fabhalta $79.09Kisqali $78.76Besponsa $77.19Darzalex $76.36Wainua $76.35Tecentriq Hybreza $75.83Paxlovid $74.83Iclusig $71.31Lumakras $70.03Tibsovo $69.62Jevtana $69.05Tecvayli $68.20Ojjaara $65.21Danziten $61.36Bavencio $59.25Stivarga $54.69Vitrakvi $54.69Eligard $54.66Neulasta $54.25Neupogen $54.25Avastin $54.25Kyprolis $54.08Orserdu $54.05Bevespi Aerosphere $53.81Phesgo $53.17Alecensa $52.64Xpovio $52.64Piqray $51.37Amvuttra $49.69Onivyde $49.37Poteligeo $49.24Lunsumio $49.20Rytelo $48.97Mi Cancer Seek $48.42
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Melo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.